Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Daiichi Sankyo
Healthtrust
Covington
Farmers Insurance
Medtronic
Deloitte
Moodys
Mallinckrodt
Cipla

Generated: August 18, 2017

DrugPatentWatch Database Preview

DESVENLAFAXINE Drug Profile

« Back to Dashboard

What is the patent landscape for Desvenlafaxine, and when can generic versions of Desvenlafaxine launch?

Desvenlafaxine is a drug marketed by Teva Pharms Usa, Alembic Pharms Ltd, Sun Pharma Global, Sandoz Inc, Actavis Labs Fl, Lupin Ltd, West-ward Pharms Int, and Mylan Pharms Inc. and is included in ten NDAs.

The generic ingredient in DESVENLAFAXINE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. There is one tentative approval for this compound. Additional details are available on the desvenlafaxine succinate profile page.

Summary for Tradename: DESVENLAFAXINE

Patents:0
Applicants:8
NDAs:10
Suppliers / Packagers: see list1
Bulk Api Vendors: see list58
Clinical Trials: see list60
Patent Applications: see list668
Drug Prices:see details
DailyMed Link:DESVENLAFAXINE at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa
DESVENLAFAXINE
desvenlafaxine fumarate
TABLET, EXTENDED RELEASE;ORAL205208-001Oct 11, 2013DISCNNoNo► Subscribe► Subscribe► Subscribe
Mylan Pharms Inc
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204095-001Jun 29, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Alembic Pharms Ltd
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204003-001Jun 29, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Alembic Pharms Ltd
DESVENLAFAXINE
desvenlafaxine
TABLET, EXTENDED RELEASE;ORAL204150-002Mar 4, 2013BCRXYesYes► Subscribe► Subscribe► Subscribe
Actavis Labs Fl
DESVENLAFAXINE SUCCINATE
desvenlafaxine succinate
TABLET, EXTENDED RELEASE;ORAL204065-002Jul 29, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Chubb
Chinese Patent Office
QuintilesIMS
Deloitte
Johnson and Johnson
Colorcon
Cipla
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot